Delivery Order SPE2DB22D1002-SPE2DB24FLCP1
- Not listed
- This is a $3,649 firm fixed-price delivery order awarded to AmerisourceBergen Drug Corporation by the Defense Logistics Agency (DLA) for the provision of GEL-ONE 30 MG/3 ML syringes. The order has an ultimate completion date of December 24, 2024. AmerisourceBergen is a major pharmaceutical distributor and healthcare solutions provider that plays a critical role in supplying medical products to federal government agencies. This delivery order is part of a larger $999,999,999 Indefinite Delivery...
- This is a firm fixed price delivery order contract awarded by the Defense Logistics Agency (DLA) Troop Support Medical to Amerisourcebergen Drug Corp, a subsidiary of Amerisourcebergen Corporation. The contract, valued at $5,290.80, is for the delivery of GEL-ONE 30 MG/3 ML SYRINGE 3ML pharmaceuticals. Amerisourcebergen Drug Corp is the prime contractor and there are no set-aside designations mentioned. The contract has a completion date of March 12, 2024. Amerisourcebergen Drug Corp also...
- This is a firm fixed price delivery order awarded by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a subsidiary of global pharmaceutical distributor Amerisourcebergen Corporation. The $21,163.20 delivery order is for GEL-ONE 30 MG/3 ML SYRINGE 3ML, with an ultimate completion date of April 16, 2024. Amerisourcebergen Drug Corp holds an indefinite delivery contract (IDC) with DLA valued up to $999,999,999.00 through December 31, 2025. This IDC serves as the primary vehicle...
- This is a federal contract award from the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a subsidiary of Amerisourcebergen Corporation, one of the largest pharmaceutical distribution companies in the world. The contract is for the delivery of GEL-ONE 30 MG/3 ML SYRINGE 3ML, a pharmaceutical product, with a ceiling value of $5,290.80. The contract has a firm fixed price pricing type and an ultimate completion date of May 24, 2024. This appears to be a delivery order issued against...
- This is a delivery order issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, for the supply of GEL-ONE 30 MG/3 ML SYRINGE 3ML medical products. The contract has a ceiling value of $10,581.60 and a period of performance through May 21, 2024. AmerisourceBergen holds a larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued up to $999,999,999.00 through December 31, 2025, which serves as the primary vehicle for...
- This is a Delivery Order awarded by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a subsidiary of Amerisourcebergen Corporation, a major pharmaceutical distribution company. The $10,228.88 contract is for the supply of GEL-ONE 30 MG/3 ML SYRINGE 3ML, a pharmaceutical product, with a completion date of May 24, 2024. Amerisourcebergen holds a larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical valued at up to $999,999,999.00 through December 31, 2025 for a...
- This is a federal delivery order contract awarded by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the supply of GEL-ONE 30 MG/3 ML SYRINGE 3ML, a medical product, with a ceiling value of $3,649.00. The contract is a firm fixed price, non-set-aside delivery order with a period of performance through July 15, 2025. Amerisourcebergen Drug Corp is the prime contractor, and there is no...
- This is a delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the supply of GEL-ONE 30 MG/3 ML SYRINGE 3ML, a medical product, with a ceiling value of $7,298.00 and a completion date of February 26, 2025. The contract is a firm fixed-price delivery order, without any set-aside requirements. AmerisourceBergen holds a significant Indefinite Delivery Contract...
- Amerisourcebergen Drug Corp, a subsidiary of Amerisourcebergen Corporation, has been awarded a $2,116.32 firm fixed price delivery order contract by the Defense Logistics Agency (DLA) to provide 4563681046 - GEL-ONE 30 MG/3 ML SYRINGE 3ML. This delivery order is part of a larger indefinite delivery contract (IDC) with a potential value of $999,999,999.00 awarded to Amerisourcebergen Drug Corp by DLA, which serves as the primary vehicle for the company to deliver pharmaceutical products and...
- The U.S. Defense Logistics Agency (DLA) awarded a $7,054.40 firm-fixed-price delivery order contract to Amerisourcebergen Drug Corp's Corporate Office division. The contract is for the delivery of 4565562938 - GEL-ONE 30 MG/3 ML SYRINGE 3ML, with a completion date of August 22, 2024. Amerisourcebergen Drug Corp is a major pharmaceutical distributor that supplies essential medical commodities, including prescription drugs, vaccines, and medical supplies, to various federal agencies and healthcare...
- SPE2DB22D1002Indefinite Delivery Contract
- SPE2DB22D1002-SPE2DB24FLCP1Delivery Order
This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp's Corporate Office Division for the supply of GEL-ONE 30 MG/3 ML SYRINGE 3ML medical products. The contract has a ceiling value of $5,290.80 and a completion date of June 13, 2024. Amerisourcebergen is a major pharmaceutical distribution company that provides a wide range of medications, medical devices, and supplies to various federal agencies, including the Department of Defense (DoD) and Veterans Affairs (VA). The company holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued up to $999,999,999.00 through December 31, 2025, which serves as the primary vehicle for Amerisourcebergen to deliver pharmaceutical products and medical supplies to DLA facilities supporting the DoD worldwide. This specific delivery order is part of that larger IDC. Amerisourcebergen also holds a smaller IDC with the Department of Justice Federal Bureau of Investigation for similar medical products and prescription drugs, valued up to $750,000 through May 2024.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $5.3k | 5/22/24 |